Silenced anti-cd28 antibodies and use thereof
CA 2432736 A1 · Owner: Fujisawa Pharmaceutical Co. Ltd. · Inventors: Tamura, Kouichi; Higashi, Yasuyuki; Ueda, Hirotsugu
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides anti-CD28 antibodies which are defective in mitogenic activity (silenced anti-CD28 antibodies) methods of producing, compositions containing the antibody and methods of immunosuppression inducing T-cell tolerance and treating organ and/or tissue transplant rejections.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 14, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 14, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 14, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.